• Carcinoid heart disease typically involves the right-sided valves of the heart. • Carcinoid valves are fixed and retracted with limited mobility. • Pathognomonic appearance of valves increases carcinoid likelihood. • Carcinoid diagnosis has intraoperative implications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451913 | PMC |
| http://dx.doi.org/10.1016/j.case.2020.05.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum and urinary 5-hydroxyindolacetic acid, serotonin, chromogranin A, and NT-proBNP for the detection of carcinoid heart disease.
Eur J Endocrinol
November 2024
Service de Biochimie et biologie moléculaire, Hospices Civils de Lyon, Bron 69500, France.
Objective: The aim of this study was to evaluate the performance of different biomarkers for the detection of carcinoid heart disease (CHD) in neuroendocrine tumours (NETs), in particular serum 5-HIAA (s5HIAA).
Design: An explorative ancillary study of the French CrusoeNET cohort.
Methods: Patients managed in the Lyon-EURACAN Center of Excellence (CoE) were included when they were aged of at least 18 years, treated and followed for an advanced/metastatic ileum or lung NET, a NET irrespective of the primary location or from unknown primary location but with clinical CS, and/or elevation of urinary 5-HIAA (u5HIAA) twice greater than the upper limit of normal.
Imaging with [Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
Lancet Oncol
August 2024
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA. Electronic address:
Background: Delta-like ligand 3 (DLL3) is aberrantly expressed on the surface of small-cell lung cancer (SCLC) and neuroendocrine prostate cancer cells. We assessed the safety and feasibility of the DLL3-targeted imaging tracer [Zr]Zr-DFO-SC16.56 (composed of the anti-DLL3 antibody SC16.
View Article and Find Full Text PDFFrom biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms.
Ther Adv Med Oncol
March 2024
Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Somatostatin analogs (SSA), specifically octreotide and lanreotide, have demonstrated antiproliferative effects in patients with neuroendocrine tumors (NET), a group of rare malignancies of diverse origin and presentation. A prominent feature of NET cells is the expression of G protein-coupled receptors called somatostatin receptors (SSTR). Although these SSTR are not uniformly present in NET, they can be instrumental in the diagnosis and treatment of NET.
View Article and Find Full Text PDFVirtual Care for Patients with Advanced Well Differentiated Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET).
Curr Oncol
February 2024
Division of Medical Oncology, The University of Ottawa, The Ottawa Hospital Cancer Centre, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
Article Synopsis
- - The study investigates the shift to virtual care for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) during the COVID-19 pandemic at the Ottawa Hospital Cancer Center from June 2019 to December 2022.
- - Out of 103 patients, a significant portion of follow-up visits (76.1%) and some consultations (17.5%) were conducted virtually, with a gradual return to in-person visits by 2022.
- - The findings indicate that virtual care played a major role in managing GEP-NET patients during the pandemic and suggests that it may enhance access to specialized care in the future.
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
BMC Cancer
September 2023
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano, ENETS Center of Excellence, Via Giacomo Venezian 1, 20133, Milan, Italy.
Background: Well-differentiated (WD) neuroendocrine tumors (NETs) are a group of rare neoplasms with limited therapeutic options. Cabozantinib is an inhibitor of multiple tyrosine kinases with a pivotal role in NET pathogenesis, including c-MET and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). LOLA is the first prospective phase II trial aiming to assess the safety and activity of cabozantinib combined with lanreotide in WD NETs of gastroenteropancreatic (GEP), thoracic and of unknown origin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!